West Michigan Rheumatology was one of the original investigational sites for the Scleroderma Clinical Trials Consortium beginning in 1994 with the landmark "High dose, Low dose d-Penicillamine Trial".
We have continued this thread of investigation by evaluating the validity of the Rodnan Scleroderma Skin Score (a primary outcome in generalized scleroderma studies) and the Raynaud's Condition Score (the primary outcome for all raynauds clinical trials). We have conducted a number of investigations of potential treatments including "d-Penicillamine", "Relaxin" for generalized, diffuse scleroderma, "dasatimib" for pulmonary fibrosis in diffuse scleroderma, and "scleroderma treatment strategies".
Michigan State University Scleroderma Program
WMR is the primary clinical site for the MSU Scleroderma Program. This is lead by Dr. Richard Neubig, MSU’s Chairman of the Department of Pharmacology. Current efforts center on preclinical studies evaluating scleroderma signaling mechanisms and new drug discovery.
Current Scleroderma & Raynauds Phenomenon Studies
This evaluates subcutaneous Actemra, an FDA approved treatment for RA, in early diffuse scleroderma. Enrollment is now active.
Cytori STAR Study
This evaluates the effectiveness of injection of autologously harvested fat stem cells into the fingers of patients with scleroderma related hand contractures. Enrollment is now active.
Want to learn more?
We have only shared a brief overview of our current research projects. If you are interested in learning more about participation, please contact our research coordinator via email using the form below. She would be happy to provide further information on specific studies via email and follow up with you on the phone to answer your questions about the details of participation. You may also reach her by calling 616.459.8088.